AbCellera Biologics Inc. ABCL Marketable Securities Unrealized Gain Loss
Marketable Securities Unrealized Gain Loss at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesUnrealizedGainLoss.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s marketable securities unrealized gain loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s marketable securities unrealized gain loss?
- AbCellera Biologics Inc. (ABCL) reported marketable securities unrealized gain loss of $200K in Q4 2025.
- How has AbCellera Biologics Inc.'s marketable securities unrealized gain loss changed year-over-year?
- AbCellera Biologics Inc.'s marketable securities unrealized gain loss decreased by 0.0% year-over-year, from $200K to $200K.
- What is the long-term trend for AbCellera Biologics Inc.'s marketable securities unrealized gain loss?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s marketable securities unrealized gain loss has grown at a -38.3% compound annual growth rate (CAGR), from $2.1M to $800K.
- What does marketable securities unrealized gain loss mean?
- Represents the change in fair value of investment securities held by the company that have not yet been sold. This metric reflects the impact of market fluctuations on the company's liquid investment portfolio.